Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Simcha raises $40M to advance cancer drug study

Simcha Therapeutics, a New Haven-based biotech focused on fighting cancer, reports it has raised $40 million in a Series B financing round. Dr. Aaron Ring,...

| By Kelley Gipson

Hartford HealthCare in partnership with Quinnipiac

Hartford HealthCare and Quinnipiac University report a new partnership to bolster training of the healthcare workforce with new programs and funding. HHC will spend $5 million over the...

| By Kelley Gipson

Artizan picks lead candidate against bowel disease

Artizan Biosciences reports that it has selected its lead product candidate,  ARZC-001, for the treatment of inflammatory bowel disease. The New Haven-based biotechnology company describes the candidate...

| By Kelley Gipson

Weekly Roundup – January 27, 2022

See the full Roundup in your browser here. CytoVeris is leveraging the convergence of powerful optical technologies, the biology of carcinogenesis, and artificial intelligence to bring...

| By Kelley Gipson

Smithsonian names Yale “detergent” top discovery

Work from the laboratory of John MacMicking in the Yale Systems Biology Institute was recently named one of 10 innovative discoveries for 2021, according to the Smithsonian...

| By Kelley Gipson

MannKInd now names Danbury its corporate home

MannKind is now designating Danbury as principal executive office in filings with the U.S. Securities and Exchange Commission, with the company having long operated an insulin...

| By Kelley Gipson

Career Newsletter

To read the full email in your browser click here. University of New Haven Virtual STEM Career Fair February 24, 2022 1:00 pm – 4:00...

| By Kelley Gipson

CaroGen Hepatitis B vaccine gets Federal funding

Farmington-based bioscience startup CaroGen reports its immunotherapy vaccine that targets chronic Hepatitis B has been recommended for $6.8 million in federal funding by the U.S. Department of Defense....

| By Kelley Gipson

Sema4 plans to buy Maryland testing firm GeneDX

Stamford’s Sema4 plans to buy genomic testing firm GeneDx of Maryland in a deal that projects $350 million in revenue for the combined companies this year. GeneDx...